Article Text

Download PDFPDF
An exploration of patients’ experiences of participation in a randomised controlled trial of the Manchester Acute Coronary Syndromes (MACS) decision rule
  1. Patricia van den Berg1,
  2. Sarah Kendal2,
  3. Helen V Alderson3,
  4. Richard Body4,5
  1. 1 Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
  2. 2 School of Human and Health Sciences, University of Huddersfield, Huddersfield, UK
  3. 3 Renal Medicine, Salford Royal NHS Foundation Trust, Salford, UK
  4. 4 Emergency Department, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
  5. 5 University of Manchester, Manchester, UK
  1. Correspondence to Professor Richard Body, Emergency Department, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UK; richard.body{at}manchester.ac.uk

Footnotes

  • Contributors RB designed the trial and contributed with HA to data acquisition. PB, RB and SK contributed substantially to the data analysis.

    PB drafted the manuscript and RB, SK and HA revised it critically for important intellectual content.

    All four authors provided final approval of the version to be published and agree to be accountable for all aspects of the work.

  • Funding This trial was funded by the UK National Institute for Health Research via a postdoctoral fellowship grant (reference PDF-2012-05-193) awarded to RB. The trial was sponsored by Central Manchester University Hospitals NHS Foundation Trust. Except for the sponsors providing the required monitoring and governance checks, the sponsors and funders of this work played no role in the design and conduct of the study; data collection; analysis; decision to publish; or preparation of the manuscript.

  • Competing interests RB has previously undertaken research involving donation of reagents without charge by Roche, Abbott, Alere, Siemens and Randox. He has accepted the provision of economy class travel and accommodation to present findings unrelated to this work at two Roche-sponsored conferences and at a scientific session sponsored by Randox.

  • Ethics approval Greater Manchester Central Research Ethics Committee, reference 13/NW/0081.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors RB designed the trial and contributed with HA to data acquisition. PB, RB and SK contributed substantially to the data analysis.

    PB drafted the manuscript and RB, SK and HA revised it critically for important intellectual content.

    All four authors provided final approval of the version to be published and agree to be accountable for all aspects of the work.

  • Funding This trial was funded by the UK National Institute for Health Research via a postdoctoral fellowship grant (reference PDF-2012-05-193) awarded to RB. The trial was sponsored by Central Manchester University Hospitals NHS Foundation Trust. Except for the sponsors providing the required monitoring and governance checks, the sponsors and funders of this work played no role in the design and conduct of the study; data collection; analysis; decision to publish; or preparation of the manuscript.

  • Competing interests RB has previously undertaken research involving donation of reagents without charge by Roche, Abbott, Alere, Siemens and Randox. He has accepted the provision of economy class travel and accommodation to present findings unrelated to this work at two Roche-sponsored conferences and at a scientific session sponsored by Randox.

  • Ethics approval Greater Manchester Central Research Ethics Committee, reference 13/NW/0081.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles